Clinical trials: Acute Congestive Heart Failure
Acute Decompensated Heart Failure
The STIM-ADHF Study
The STIM-ADHF Study is a multi-center, observational study to assess the performance and safety of the CPNS System in patients with ADHF.
- Trial name
- NCT05313438
- Testing
- CPNS Therapy
- Where
- 6 sites in Hungary, Poland and 1 more
- Volunteers
- 13 people
- Sponsor
- Cardionomic Inc.
Cardiogenic Shock, Heart Failure
Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock
The Elevate™ CS Clinical Feasibility Study is designed to evaluate the initial safety, effectiveness, and device performance of the Magenta Elevate™ System in patients with cardiogenic shock due to isolated or predominant left…
- Conditions
- Cardiogenic Shock, Heart Failure, Acute Myocardial Infarction (AMI)
- Trial name
- NCT07293923
- Testing
- Elevate™ System
- Where
- 8 sites in Georgia, Israel
- Volunteers
- 10 people
- Sponsor
- Magenta Medical Ltd.
Heart Failure, Left Bundle Branch Block
High Septal Pacing for Cardiac Resynchronization Therapy
The purpose of this acute study is to perform a preliminary investigation of high septal right ventricular pacing in the vicinity of the His bundle region as an alternate or adjunctive means for cardiac resynchronization in…
- Conditions
- Heart Failure, Left Bundle Branch Block, Heart Disease
- Trial name
- HISTORY (NCT01325480)
- Testing
- Cardiac Pacing
- Where
- Hong Kong
- Volunteers
- 15 people
- Sponsor
- Boston Scientific Corporation
Heart Failure, Cardiorenal Syndrome
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy.
- Conditions
- Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF
- Trial name
- DRAIN-HF (NCT05677100)
- Testing
- Aortix System
- Where
- 50 sites in United States, Hungary
- Volunteers
- 320 people
- Sponsor
- Procyrion
Heart Failure
Monitor Patients With Acute Heart Failure
This is a prospective, multi-center, non-randomized study to evaluate performance of an external monitor for heart failure patients
- Trial name
- ACUTE (NCT00919828)
- Testing
- Avivo System
- Volunteers
- 60 people
- Sponsor
- Corventis, Inc.
Heart Failure, Heart Decompensation
A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)
A placebo controlled, double-blind and randomized study to assess different doses of a new drug (BAY58-2667) given intravenously, to evaluate if it is safe and can help to improve the well-being of patients with acute…
- Trial name
- COMPOSE EARLY (NCT01064037)
- Testing
- Cinaciguat (BAY58-2667)
- Where
- 70 sites in United States, Canada and 14 more
- Volunteers
- 62 people
- Sponsor
- Bayer
Renal Insufficiency, Congestive Heart Failure
Study to Assess the Safety and Tolerability of IV Tonapofylline in Subjects With Acute Decompensated Heart Failure (ADHF) and Renal Insufficiency
The purpose of the current study is to assess the safety and tolerability of intravenous tonapofylline.
- Trial name
- TRIDENT-1 (NCT00709865)
- Testing
- tonapofylline
- Where
- 189 sites in United States, Argentina and 16 more
- Volunteers
- 420 people
- Sponsor
- Biogen
Heart Failure With Preserved Ejection Fraction
Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects
A Multi-Center, Unblinded, Single-Arm Study to Evaluate Sex Differences in the Acute Effects of PL-3994 on Myocardial cGMP Enhancement and Hemodynamics in Heart Failure with Preserved Ejection Fraction
- Trial name
- NCT04318145
- Testing
- PL-3994 Aqueous Intravenous Solution Dose Ascention, PL-3994 Aqueous Intravenous Solution Single Dose
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Palatin Technologies, Inc
Chronic Renal Insufficiency, Diabete Mellitus
Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure
To evaluate cardio-renal and overall safety profile of GE 145 320 mg I/ml Injection when compared to iopamidol 370 mg I/mL. The study will focus on elderly subjects with either chronic renal insufficiency, or diabetes mellitus…
- Conditions
- Chronic Renal Insufficiency, Diabete Mellitus, Congestive Heart Failure
- Trial name
- NCT01252810
- Testing
- GE-145
- Where
- United States
- Volunteers
- 284 people
- Sponsor
- GE Healthcare
Hypervolemic Hyponatremia
International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia
To demonstrate that after 12 weeks of open-label lixivaptan treatment, serum sodium is maintained in hyponatremic patients continuing to receive lixivaptan compared to placebo during the 4 week double blind treatment period.
- Trial name
- NCT00876876
- Testing
- Lixivaptan
- Volunteers
- 300 people
- Sponsor
- CardioKine Inc.
Acute Decompensated Heart Failure
Gas Exchange for Predicting Hospital Heart Failure Readmissions
To determine whether, and if so, which gas exchange parameters measured on the Shape-HF Cardiopulmonary Exercise Testing System predict 30 and 180 day re-hospitalization in subjects discharged from hospitalization for an episode…
- Trial name
- NCT01960218
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Shape Medical Systems, Inc.
Unstable Angina, Acute Myocardial Infarction
Prevalence of Sleep Disordered Breathing
A novel technique in identifying unspecified sleep apnea has been developed. This technique uses signals typical acquired from a bedside monitor that is found in critical care environments.
- Conditions
- Unstable Angina, Acute Myocardial Infarction, Congestive Heart Failure
- Trial name
- NCT01011647
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- GE Healthcare
Heart Failure, Acute Myocardial Infarction
Eplerenone in Heart Failure Treatment
Beta-blockers should be administered to all patients with heart failure stage II to IV according to NYHA.Beta-blockers reduce mortality and hospitalizations and improve the operational phase for all categories of patients with…
- Conditions
- Heart Failure, Acute Myocardial Infarction, Hypertension
- Trial name
- INOSET (NCT02344199)
- Where
- 3 sites in Greece
- Volunteers
- 450 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Heart Decompensation
Study of the Sudden Heart Failure Participant Population in the US
An observational study using data from a large US electronic health record database to find participants hospitalized with ADHF who do not have a concurring heart attack
- Trial name
- NCT03566264
- Testing
- Non-Interventional
- Where
- 2 sites in United States
- Sponsor
- Bristol-Myers Squibb
Acute Decompensated Heart Failure
REducing 30-day ADMIssions in posT-discharge Subjects (READMIT)
The purpose of this observational study is to collect and characterize multiple physiologic data from a broad subset of subjects with acute heart failure (HF) Changes in physiologic data are expected to correlate with 30-day…
- Trial name
- READMIT-HF (NCT01574144)
- Testing
- AVIVO™ PiiX Patch Monitor System
- Where
- 8 sites in United States, Australia
- Volunteers
- 70 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Acute Decompensated Heart Failure
EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU)
The objective of this study is to prospectively compare decongestive therapy administered by the Reprieve DMS system to Optimal Diuretic Therapy (ODT) in the treatment of patients diagnosed with acute decompensated heart failure…
- Trial name
- FASTR-EU (NCT06362668)
- Testing
- Reprieve Decongestion Management System, Diuretic (furosemide, bumetanide, torsemide, hydrochlorothiazide, and/or acetazolamide)
- Where
- 2 sites in Netherlands, Poland
- Volunteers
- 12 people
- Sponsor
- Reprieve Cardiovascular, Inc
Acute Myocardial Infarction
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.
- Trial name
- PARADISE-MI (NCT02924727)
- Testing
- LCZ696 (sacubitril/valsartan), Ramipril, Valsartan
- Where
- 486 sites in United States, Argentina and 39 more
- Volunteers
- 5,669 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma, Myelodysplastic Syndromes
A Study of Special Use Results Surveillance of Revlimid 5mg Capsules
To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in all patients who are treated with it under the actual condition of use pursuant to the conditions of approval. 1.
- Trial name
- NCT02921802
- Where
- Japan
- Volunteers
- 4,626 people
- Sponsor
- Celgene
Acute Decompensated Heart Failure
DR REGISTRY: Prospective Observational Study of ADHF Patients With Insufficient Response to Diuretics
The study objective is to observe and measure clinical outcomes, urine output, and safety events occurring during standard medical treatment of ADHF patients deemed to have insufficient diuretic response.
- Trial name
- NCT04877652
- Testing
- Standard of care
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Revamp Medical Ltd.
Acute Decompensated Heart Failure
Study of the Safety of BMS-986259 in Participants With Post-Acute Decompensated Heart Failure
The purpose of the study is to assess the safety of BMS-986259 in stable participants hospitalized for acute decompensated heart failure.
- Trial name
- NCT04318093
- Testing
- BMS-986259
- Where
- 18 sites in Argentina, Czechia and 4 more
- Volunteers
- 25 people
- Sponsor
- Bristol-Myers Squibb